EpiVax

EpiVax uses "immunoinformatics" computer modeling, gene sequencing and molecular immunology to develop new vaccines and to improve the immunogenicity profiles of new drugs. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. EpiVax won the prestigious AAPS Innovation award for its Tregitope technology. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). EpiVax’ 22 employees are “an incredibly creative group,” says De Groot, the company’s CEO and CSO. “We try to foster a balance between customer focus, Yankee frugality, and intellectual curiosity,” she says. “The critical components of our company’s innovations process are free thought, unencumbered imagination and an ability to connect the dots.” The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.”Show more